Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1646 1674
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18249807 | PROTEINS COMPRISING DELTA-LIKE LIGAND 3 (DLL3) ANTIGEN BINDING DOMAINS AND THEIR USES | Non-Final OA | Janssen Biotech, Inc. |
| 18359483 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17924612 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL STORAGE DISORDERS | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18432780 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18400667 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Non-Final OA | Washington University |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | Final Rejection | BioNTech SE |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | Non-Final OA | Research Development Foundation |
| 18003484 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | Non-Final OA | SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy